Meyer-Lindenberg, A., Nielson Arendt, J., Such, P., Lemming, O. M., Zambori, J., Buller, R., & Goltz, C. v. d. (2022). A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia. European neuropsychopharmacology, 61, . https://doi.org/10.1016/j.euroneuro.2022.05.009
Chicago-Zitierstil (17. Ausg.)Meyer-Lindenberg, Andreas, Jacob Nielson Arendt, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, und Christoph von der Goltz. "A Double-blind, Randomized, Placebo-controlled Proof of Concept Study of the Efficacy and Safety of Lu AF11167 for Persistent Negative Symptoms in People with Schizophrenia." European Neuropsychopharmacology 61 (2022). https://doi.org/10.1016/j.euroneuro.2022.05.009.
MLA-Zitierstil (9. Ausg.)Meyer-Lindenberg, Andreas, et al. "A Double-blind, Randomized, Placebo-controlled Proof of Concept Study of the Efficacy and Safety of Lu AF11167 for Persistent Negative Symptoms in People with Schizophrenia." European Neuropsychopharmacology, vol. 61, 2022, https://doi.org/10.1016/j.euroneuro.2022.05.009.